By 2035, an estimated 25% of the worlds population will be classified as obese. As the obesity epidemic intensifies, 2024 stands out as a pivotal moment in the fight against this condition. For the first time, the healthcare industry is witnessing the emergence of a major new market for effective prescription medications that promise unprecedented impacts not only on obesity but also on related health issues such as diabetes, cardiovascular diseases, and metabolic disorders.This panel will feature treatment, as well as Eli Lilly and Novo Nordisk—two pharmaceutical giants at the forefront of this revolution. They will explore obesity as a disease, a social construct, and a burgeoning market industry. The discussion will cover how innovative therapies and market shifts are poised to redefine our understanding of obesity, offering new hope for millions while reshaping the future of global healthcare. The rise of this new mega-sized therapy market could even be the catalyst for the debut of the world’s first trillion-dollar life sciences company—a milestone that is now within reach. Is the current unprecedented willingness to pay out of pocket for these new therapies a boon or bane for humanity?